Business Wire

BEARINGPOINT

17.11.2022 08:06:39 CET | Business Wire | Press release

Share
Kao outsmarts the growing demands of e-commerce by automating the return-order process – BearingPoint client success story

E-commerce trends induced by the global pandemic took online purchasing to the next level of development. This expansion led to significant changes for all online sales and logistics processes, including an increased need to optimize customer return-order processes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221116005790/en/

In its recent client story, BearingPoint shows how it supported Kao, one of the leading global manufacturers of hair care products and cosmetics, in leveraging innovative technology to upgrade its return-order tasks.

Staying competitive in the fast-moving consumer goods (FMCG) market requires strong interconnectivity, real-time data transmission and reliable processes. In the past, managing an end-to-end process for return orders was labor-intensive and involved many employees, multiple IT devices and coordinating access to various software systems. Even when all these needs were met, the process often generated high costs and human errors in data entry along with strong dependencies.

The Kao Group aimed to leave this scenario behind and leverage innovation to gain efficiency. The company needed a better way to handle its return-order tasks, which at the time required a multi-step processing of documents and the input of data into SAP each time a request was received.

Management and technology consultancy BearingPoint worked with Kao to analyze the company’s existing processes to understand how its warehouse movements and activities – such as goods receiving, put away, storage and shipping – were translated into SAP system return-order data. A technical “to be” process was designed, which covered future workflow steps in detail, transaction loads, business rules, error handling, risks, dependencies and unknown exceptions.

Happy users and even more satisfied customers

“The RPA solution we used for Kao has made the company much more competitive. It not only automated the return order processes but freed up employees to do more value-added work. RPA solutions can benefit businesses in all industries, and it’s incredible how much they free up the workforce,” said Andreas Fitz, Partner at BearingPoint.

By leveraging UiPath’s RPA, BearingPoint developed a solution that formatted return-order email information automatically to create the required documents in SAP. The solution uses a bot first to extract relevant information – like original sales order, customer number, material code, and unrestricted and blocked quantities. It then immediately performs return orders, inbound delivery, and goods receipt transactions in SAP. The process is completed by sending out email notifications to Kao’s Customer Service department.

“With BearingPoint at our side, we were able to streamline and reduce a lot of manual work in a cumbersome internal process! Setting the bot solution live led to happy users and even more satisfied customers!” said Suyin Boehnke, SAP Senior Business Relationship Manager SCM EMEA, The Kao Group.

Kao can now process all its return-order tasks faster and more consistently, regardless of demand or data volume peaks. By using automation, the required documentation is processed 24/7 without significant interruptions or delays. The RPA solution provides transparent and accurate inventory data for further process improvements, such as stock and demand planning. Kao’s products that are eligible for resale are inserted into the marketplace workflow rapidly, thus reaching customers faster.

The company can now rely on an efficient process involving no additional interfaces, system access or need for human interaction, resulting in substantial cost optimization. The bot removes any risk of human error while freeing up time for Kao’s staff to work on other business-related, value-adding activities.

You can read the full client success story here: https://www.bearingpoint.com/en/insights-events/client-stories/kao-return-order-process-automation/

About Kao

Kao creates high-value-added products and services that provide care and enrichment for the lives of all people and the planet. Through its portfolio of over 20 leading brands – such as Oribe, Attack, Bioré, Goldwell, Jergens, John Frieda, Kanebo, Laurier, Merries and Molton Brown – Kao is part of the everyday lives of people in Asia, Oceania, North America, and Europe. Combined with its chemical business, which contributes to a wide range of industries, Kao generates about 1,420 billion yen in annual sales. Kao employs about 33,500 people worldwide and has 135 years of history in innovation.

About BearingPoint

BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.

BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 13,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.

For more information, please visit:

Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005790/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release

-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye